Pfizer plots big outsourcing push
The U.S.'s loss is Asia's gain. Pfizer is the latest drug maker to announce it's looking to outsource a big chunk of its manufacturing, mostly to Asia--30 percent, to be exact. Currently, the company farms out about 15 percent.
The motivation, of course, is cost-cutting. As part of a company-wide restructuring earlier this year, Pfizer announced it would shut down plants in Brooklyn, NY, and Omaha, NE, plus sell a plant in Germany. Presumably the company intends to hire others to take over that work, and perhaps other projects as well.
Meanwhile, the company launched its tender offer for Coley Pharmaceutical Group at $8 a share. Some 27 percent of Coley's shareholders already pledged to accept Pfizer's offer, which expires December 28.
- see the outsourcing article from CNN Money
- read the latest on the Coley deal in a Pfizer news release
Related Articles:
Pfizer cuts 10,000 jobs. Report
Pfizer pares down Ann Arbor campus. Report
Novartis maps $100M R&D complex in China. Report
Sanofi to build vaccine plant in China. Report
Comments
Post new comment
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets

